Integra Therapeutics, member of CataloniaBio & HealthTech, will present positive fata from ex vivo and in vivo preclinical studies that demonstrates the potential of its FiCAT gene-writing platform for developing advanced therapies in the field of paediatric hepatology at the Advanced therapies Europe congress. 

Avencia Sánchez-Mejías, CEO and co-founder of Integra Therapeutics, will analyse the data in a conference titled “FiCAT Innovative Gene Writing Platform for Advanced Therapies” on 7 September at 10:30 am local time, as part of a panel on innovate technologies as a driving force for successful commercialisation of cell and gene therapies on the European market. 

Integra Therapeutics is a global leader in creating next-generation gene writing tools to make advanced therapies safer and more effective. The company was founded in 2020 as a spin-off of Pompeu Fabra University (UPF) by Dr. Marc Güell and Dr Avencia Sánchez-Mejías and is based at the Barcelona Biomedical Research Park (PRBB).